By Hal M. Bundrick
NEW YORK (MainStreet) �One step forward, two steps back. While Americans are saving more for retirement, many are also going even deeper into debt. The treadmill is starting to run in reverse. Over 60% of workers participating in an employer sponsored retirement plan accumulated more debt than they contributed to their retirement savings between 2010 and 2011, according to research conducted by HelloWallet.com.
The study looked at data from the Federal Reserve and the U.S. Census Bureau and found that one in five participants in 401(k) retirement plans particularly added more credit card debt to their family balance sheet than they contributed to retirement savings.
10 Best Gas Stocks To Buy Right Now: Umpqua Holdings Corp (UMPQ)
Umpqua Holdings Corporation (Umpqua) is a financial holding company. Umpqua has two principal operating subsidiaries, Umpqua Bank (the Bank) and Umpqua Investments, Inc. (Umpqua Investments). The Bank is primarily engaged in the business of commercial and retail banking and the delivery of retail brokerage services. The Bank provides a range of banking, wealth management, mortgage banking and other financial services to corporate, institutional and individual customers. Umpqua Investments is a broker-dealer and investment advisor with offices in Portland, Lake Oswego, Medford, Oregon, and in many Umpqua Bank stores. Umpqua Investments offers a range of investment products and services, including stocks, fixed income securities (municipal, corporate, and government bonds, Certificate of Deposits (CDs), and money market instruments), mutual funds, annuities, options, retirement planning, money management services and life insurance. In December 2011, the Bank launched a commercial real estate division. In November 2012, the Company acquired Circle Bancorp, parent company of Circle Bank. In July 2013, Umpqua Holdings Corp completed its acquisition of Financial Pacific Holding Corp.
The Company offers a Switch Kit, which allows a customer to open a primary checking account with Umpqua Bank in less than 10 minutes. Other avenues, through which customers can access its products, include its Website equipped with an e-switchkit, which includes Internet banking through umpqua.online, mobile banking, and its 24-hour telephone voice response system. Umpqua Private Bank serves high net worth individuals with liquid investable assets by providing customized financial solutions and offerings. Umpqua private bank works collaboratively with the Bank�� affiliate retail brokerage Umpqua Investments and with the independent capital management firm Ferguson Wellman Capital Management. Umpqua Investments provides a range of brokerage services, including equity and fixed income products, mutual funds, annui! ties, options, retirement planning and money management services. Additionally, Umpqua Investments offers life insurance policies. At December 31, 2011, Umpqua Investments had 41Series seven-licensed financial advisors serving clients at three stand-alone retail brokerage offices and Investment Opportunity Centers located in many Bank stores.
Lending Activities
Umpqua offers loans for business and commercial customers, including accounts receivable and inventory financing, equipment loans, international trade, real estate construction loans and permanent financing and SBA program financing, as well as capital markets and treasury management. Additionally, it offers designed loan products for small businesses through its Small Business Lending Center. It also has a business banking division to increase lending to small and mid-sized businesses. The Company is also engaged in initiatives that continue to diversify the loan portfolio, including a focus on commercial and industrial loans in addition to financing owner-occupied properties.
Real estate loans are available for construction, purchase and refinancing of residential owner-occupied and rental properties. Borrowers can choose from a variety of fixed and adjustable rate options and terms. It sells residential real estate loans that originate into the secondary market. It also supports the Home Affordable Refinance Program and Home Affordable Modification Program. The Bank also provide loans to individual borrowers for a variety of purposes, including secured and unsecured personal loans, home equity and personal lines of credit and motor vehicle loans. The Bank makes both secured and unsecured loans to individuals and businesses. During 2011, its commercial real estate, commercial, residential, and consumer and other represented approximately 64%, 25%, 10%, and 1%, respectively, of the total non-covered loan and lease portfolio.
Source of Funds
The Company offers an array of deposit p! roducts, ! including non-interest-bearing checking accounts, interest-bearing checking and savings accounts, money market accounts and certificates of deposit. These accounts earn interest at rates established by management based on market factors. It also offers a seniors program to customers over fifty years old, which includes an array of banking services and other amenities, such as purchase discounts, vacation trips and seminars.
Investment Activities
As of December 31, 2011, Umpqua's portfolio of investments securities included securities issued by United States Treasury and agencies, and residential mortgage-backed securities and collateralized mortgage obligations. It also includes obligations of states and political subdivisions, other debt securities, and investments in mutual funds and other equity securities.
Advisors' Opinion:- [By Roberto Pedone]
Umpqua (UMPQ) is engaged in the business of commercial and retail banking and the delivery of retail brokerage services. This stock closed up 5% at $17.11 in Monday's trading session.
Monday's Volume: 2.16 million
Three-Month Average Volume: 686,781
Volume % Change: 235%From a technical perspective, UMPQ ripped sharply higher here right off its 50-day moving average of $16.51 with strong upside volume. This move is quickly pushing shares of UMPQ within range of triggering a big breakout trade. That trade will hit if UMPQ manages to take out Monday's intraday high of $17.46 and then once it clears its 52-week high at $17.48 with high volume.
Traders should now look for long-biased trades in UMPQ as long as it's trending above its 50-day at $16.51 or above more near-term support at $16 and then once it sustains a move or close above those breakout levels with volume that's near or above 686,781 shares. If that breakout hits soon, then UMPQ will set up to enter new 52-week-high territory above, which is bullish technical price action. Some possible upside targets off that breakout are $20 to $23.
Top 5 Heal Care Companies To Watch For 2014: PowerShares International Dividend Achievers Portfolio (PID)
PowerShares International Dividend Achievers Portfolio (the Fund) seeks to replicate, before fees and expenses, the International Dividend Achievers Index (the Index). The Fund invests in sectors, including financials, utilities, consumer staples, commercial banks, insurance, utilities and information technology. PowerShares Capital Management LLC is the adviser of the Fund.
The Index seeks to identify an international group of American Depository Receipts that have qualified as International Dividend Achievers. The Index is designed to track the performance of dividend paying American Depository Receipts and non-United States common or ordinary stocks trading on the NYSE, NADDAQ or AMEX.
Advisors' Opinion:- [By Editor , DividendChannel.com]
According to the ETF Finder at ETF Channel, Enbridge stock is an underlying holding representing 1.97% of the Powershares International Dividend Achievers ETF (PID), which holds $20,709,837 worth of ENB shares.
- [By Carlton Delfeld]
Second, add to the mix, one of my long-time favorite ETFs, the PowerShares International Dividend Achievers (PID).
To get into this exclusive basket, companies have to have a record of increasing dividends for five consecutive years. The United Kingdom and Canada make up 50% of its holdings with the US at only 6%.
Top 5 Heal Care Companies To Watch For 2014: NanoViricides Inc (NNVC)
NanoViricides, Inc., incorporated on April 1, 2005, is a development-stage company. The Company is a nano-biopharmaceutical (nanomedicine) company whose business goals are to discover, develop and commercialize therapeutics to advance the care of patients suffering from life-threatening viral infections. The Company has several drugs in various stages of early development. The Company�� drugs are based on several patents, patent applications, provisional patent applications, and other property held by TheraCour Pharma, Inc. (TheraCou), to which the Company has exclusive licenses in perpetuity for the treatment of human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Influenza including Asian Bird Flu Virus (INF), Herpes Simplex Virus (HSV), Hepatitis C Virus (HCV), Hepatitis B Virus (HBV), and Rabies. As of June 30, 2012, the Company had six drug development programs: Oral FluCideTM, against all Influenzas; a Piggy-back version of Flucide for hospitalized patients; nanoviricide eye drops against adenoviral EKC and herpes keratitis; HIVCide - I against HIV/AIDS; HerpeCide - I skin cream formulation for herpes cold sores and genital warts, and DengueCide, a broad spectrum nanoviricide designed to attack all types of dengue viruses and expected to be effective in the Severe Dengue Disease syndromes including Dengue Hemorrhagic Fever (DHS) and Dengue Shock Syndrome (DSS). As of June 30, 2012, it had engaged in organizational activities, sourcing compounds and materials, developing novel compounds and nanomaterials, and experimentation with studies on cell cultures and animals. In September 2011, NanoViricides Inc's Inno-Haven LLC acquired a light industrial building.
The Company's product development programs are divided into three sectors: commercially important diseases, neglected tropical diseases (NTD��) and biosecurity/biodefense, and advanced technologies. The Company has collaborations with KARD Scientific, Inc., MA. and Southern Research Institute, AL for influenza viruse! s; National (Central) Institute of Hygiene and Epidemiology (NIHE) (Vietnam), for H5N1 avian flu; The Long Island Jewish Medical System, Feinstein Institute of Medical Research (LIJMS), NY and TheVac, LLC. for viral diseases of the eye (adenoviruses, herpesviruses - epidemic kerato-conjunctivitis (EKC), Herpes Keratitis); TheVac, LLC and Northeastern Ohio Medical University (NEOMED) for herpes virus infections; University of California at Berkeley for dengue hemorrhagic fever viruses; Center for Disease Control and Prevention (CDC) and National (Central) Institute of Hygiene and Epidemiology for rabies virus. The Company has developed lead drug candidates against a number of viral diseases.
The Company had consolidated all of its influenza drug programs into a single pan-influenza FluCide program. It is developing a single drug for all influenzas, whether pandemic, epidemic, seasonal, novel, emerging, human, swine, or avian. It is developing a nanoviricide against adenoviral EKC. The nanoviricide eye drug candidate is formulated as simple eye drops. It is developing an anti-HSV nanoviricide skin cream formulation for direct application to the lesions. It has designed the anti-HIV nanoviricides using rational drug design principles. The ligands it has designed in the case of HIV-1 are thought to be broadly neutralizing. In-silico modeling indicates that its ligands dock to the conserved CD4 binding site of gp120 of HIV-1. The Company is working on developing anti-Dengue therapeutics. Dengue is an important NTD. Its RabiCide program has resulted in candidates that have enabled survival of 20% to 30% of infected animals after disease has set in, using a particular animal model.
The Company competes with Roche, Glaxo SmithKline, BioCryst Pharmaceuticals, Inc., Gilead, Bristol-Myers Squibb Company (BMS), Roche, Boehringer Ingelheim, Merck & Co., Inc. (Merck), Valeant, Schering, Pharmassett, Vertex, Intermune, Achillion and Novartis.
Advisors' Opinion:- [By Roberto Pedone]
One under-$10 nano-biopharmaceutical player that's starting to trend within range of triggering a big breakout trade is Nanoviricides (NNVC), which engages in the discovery, development and commercialization of anti-viral therapeutics primarily in the U.S. This stock has been ripping to the upside so far in 2013, with share up big by 198%.
If you take a look at the chart for Nanoviricides, you'll notice that this stock has recently formed a double bottom chart pattern at $4.55 to $4.52 a share. Following that bottom, shares of NNVC have now started to uptrend and move within range of triggering a big breakout trade. That trade will hit if NNVC manages to take out the upper-end of its recent sideways trading chart pattern, which has seen NNVC trend between $4.55 and $5.74 a share.
Traders should now look for long-biased trades in NNVC if it manages to break out above some near-term overhead resistance levels at Friday's high of $4.94 a share to its 50-day moving average of $5.28 a share, and then once it takes out some more key overhead resistance levels at $5.72 to $5.74 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average volume of 234,994 shares. If that breakout triggers soon, then NNVC will set up to re-test or possibly take out its next major overhead resistance levels at $6.50 to its 52-week high at $7.59 a share.
Traders can look to buy NNVC off weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at $4.55 to $4.52 a share. One can also buy NNVC off strength once it starts to clear those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
Top 5 Heal Care Companies To Watch For 2014: Nordson Corporation(NDSN)
Nordson Corporation manufactures equipment used for precision dispensing, testing and inspection, and surface preparation and curing. Its Adhesive Dispensing Systems segment manufactures equipment for applying adhesives, lotions, and liquids to disposable products; automated adhesive dispensing systems for the food and beverage, and packaged goods industries; hot melt and cold glue adhesive dispensing systems for the paper and paperboard converting industries; adhesive and sealant dispensing systems for bonding or sealing plastic, metal, and wood products; and laminating and coating systems to manufacture continuous-roll goods in the nonwovens, textile, paper, and flexible-packaging industries. The company?s Advanced Technology Systems segment comprises automated gas plasma treatment systems used to clean and condition surfaces for the semiconductor, medical, and printed circuit board industries; controlled manual and automated systems for applying materials in customer pr ocesses requiring precision and material conservation; ultraviolet equipment used in curing and drying operations for specialty coatings, semiconductor materials, and paints; and bond testing and automated optical and x-ray inspection systems used in the semiconductor and printed circuit board industries. Its Industrial Coating Systems segment provides automated and manual dispensing systems used for applying coatings, paint, finishes, sealants, and other materials. Nordson Corporation markets its products in the United States and internationally through a direct sales force, as well as through qualified distributors and sales representatives. It serves various markets, including the appliance, automotive, bookbinding, container, converting, electronics, food and beverage, furniture, life sciences and medical, metal finishing, non woven, packaging, and semiconductor industries. The company was founded in 1935 and is headquartered in Westlake, Ohio.
Advisors' Opinion:- [By Lauren Pollock]
Nordson Corp.'s(NDSN) fiscal fourth-quarter earnings fell 12% on weaker demand, though the maker of dispensing equipment noted improvement in recent order trends.
No comments:
Post a Comment